Soligenix (SNGX) Up 56% on Forthcoming Data for First Potential Ricin Vaccine according to : equities

Soligenix's RiVax vaccine, when formulated with ThermoVax, the company's proprietary vaccine heat stabilization technology, has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models. But a press release like today's signals extreme confidence in the ricin vaccine development and speaks well to the underlying fundamentals of the company's overall clinical program. NewsThe biggest gainer in Wednesday's market has been Soligenix (SNGX), which traded as high as $5.08 this morning, almost doubling its $2.57 close on Tuesday. From the CDC: If ricin is ingested, initial symptoms typically occur in less than 6-12 hours include nausea, vomiting, and abdominal pain, and can rapidly progress to include severe dehydration and kidney and liver problems. DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com.




Shares are surging on optimism for the development of the Princeton, New Jersey-based biotech's proprietary ricin toxin Vaccine, or RiVax for short. When formulated with ThermoVax, Soligenix's proprietary vaccine heat stabilization technology, RiVax has demonstrated significantly enhanced thermostability and 100% protection in preclinical ricin aerosol challenge models. While impressive, the stock is still far below the $8+ level before the drop began in October. These data are scheduled to be presented at the 20th Annual Conference on Vaccine Research, being held April 24-26 in Bethesda, Maryland. There are presently no effective treatments for ricin poisoning, which can cause death within several days of exposure.

Efficacy Results from Soligenix's Ricin Toxin Vaccine Program to be Presented at the 20th Annual Conference on Vaccine Research

With RiVax™, Soligenix is a world leader in the area of ricin toxin vaccine research. About RiVax™RiVax™ is Soligenix's proprietary heat stable recombinant subunit vaccine developed to protect against exposure to ricin toxin. RiVax™ contains a genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the toxicity of the ricin molecule. Ricin toxin illness causes tissue necrosis and general organ failure leading to death within several days of exposure. Details regarding the annual conference can be found here.


collected by :Lucy William

To follow all the new news about Health care